CSIMarket Company Name, Ticker, Suppliers, else..


Tg Therapeutics Inc   (NASDAQ: TGTX)
Other Ticker:  
 

Tg Therapeutics Inc

TGTX's Fundamental analysis



Looking into Tg Therapeutics Inc growth rates, revenue grew by 421.83 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 40

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.75 %

Tg Therapeutics Inc realized net income compared to net loss a year ago in III. Quarter 2024

• More on TGTX's Growth


Tg Therapeutics Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Tg Therapeutics Inc PEG ratio is at -0.28 Company is currently trading with Price to Cash flow multiple of 32.04 in trailing twelve-month period.
Company
43.42
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 12.99.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.23.


• More on TGTX's Valuation
 
 Total Debt (Millions $) 244
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,098,392
 Net Income/Employee (TTM) $ 323,813
 Receivable Turnover (TTM) 5.09
 Tangible Book Value (Per Share $) 1.20

Tg Therapeutics Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Tg Therapeutics Inc PEG ratio is at -0.28 Company is currently trading with Price to Cash flow multiple of 32.04 in trailing twelve-month period.
Company
43.42
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 12.99.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.23.

Tg Therapeutics Inc Price to Book Ratio is at 26.14 lower than Industry Avg. of 68.99. and higher than S&P 500 Avg. of 0.01

• More on TGTX's Valuation

•  Market Capitalization (Millions $) 5,024
•  Shares Outstanding (Millions) 161
•  Employees 352
•  Revenues (TTM) (Millions $) 387
•  Net Income (TTM) (Millions $) 114
•  Cash Flow (TTM) (Millions $) 157
•  Capital Exp. (TTM) (Millions $) 0
•  Total Debt (Millions $) 244
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 1,098,392
•  Net Income/Employee(TTM) $ 323,813
•  Receivable Turnover Ratio (TTM) 5.09
•  Tangible Book Value (Per Share $) 1.20

•  Market Capitalization (Millions $) 5,024
•  Shares Outstanding (Millions) 161
•  Employees 352
•  Revenues (TTM) (Millions $) 387
•  Net Income (TTM) (Millions $) 114
•  Cash Flow (TTM) (Millions $) 157
•  Capital Exp. (TTM) (Millions $) 0


    TGTX's Profitability Comparisons
Tg Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 14.82 % from 12 % in II. Quarter.

Tg Therapeutics Inc net profit margin of 4.63 % is currently ranking no. 54 in Major Pharmaceutical Preparations industry, ranking no. 157 in Healthcare sector and number 1856 in S&P 500.


Profitability by Segment
Total 4.63 %



  Ratio
•   Capital Ratio (MRQ) 4.59
•  Total Debt to Equity (MRQ) 1.27
•  Tangible Leverage Ratio (MRQ) 2.01
•  Asset Turnover Ratio (TTM) 0.93
•  Inventory Turnover Ratio (TTM) 0.38



Tg Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 14.82 % from 12 % in II. Quarter.

Tg Therapeutics Inc net profit margin of 4.63 % is currently ranking no. 54 in Major Pharmaceutical Preparations industry, ranking no. 157 in Healthcare sector and number 1856 in S&P 500.

• More on TGTX's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com